Search | IOVS | ARVO Journals

Showing 1 – 20 of 69

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Factor XIIa inhibition protects against VEGF-induced neuroretinal dysfunction in mice

Allen Clermont; Nivetha Murugesan; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3144.

ARVO Annual Meeting Abstract June 2023

Factor XII contributes to VEGF-induced retinal edema and neuroretinal responses in mice

Allen Clermont; Nivetha Murugesan; Tuna Ustunkaya; Lloyd Aiello; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5411.

Retina August 2020

Vascular Density of Deep, Intermediate and Superficial Vascular Plexuses Are Differentially Affected by Diabetic Retinopathy Severity

PDF

Mohamed Ashraf; Konstantina Sampani; Allen Clermont; Omar Abu-Qamar; Jae Rhee; Paolo S. Silva; Lloyd Paul Aiello; Jennifer K. Sun
TAGS: diabetic retinopathy, eye, nonproliferative diabetic retinopathy, software
Invest. Ophthalmol. Vis. Sci.. 2020; 61(10):53. https://doi.org/10.1167/iovs.61.10.53

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Vascular endothelial growth factor (VEGF) induces retinal edema and neuroretinal dysfunction in diabetic rats.

Allen C Clermont; Nivetha Murugesan; Lloyd P Aiello

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1385.

ARVO Annual Meeting Abstract June 2020

Novel oral plasma kallikrein inhibitor KV998076 is protective against intravitreal VEGF and TNFα induced retinal edema and neuroretinal dysfunction

Nivetha Murugesan; Allen C Clermont; Stephen Pethen; Lily Li; Edward Duckworth; Sally L Hampton; Edward Feener

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4863.

ARVO Annual Meeting Abstract July 2019

Identification of Photoreceptor Protein, Retinol Binding Protein 3 (RBP3), as a Protective Factor for Diabetic Retinopathy

Ward Fickweiler; Hisashi Yokomizo; Kyoungmin Park; Allen C Clermont; Yasutaka Maeda; Samantha M Paniagua; I-Hsien Wu; David Pober; Vanessa Bahnam; Robert L Avery; Timothy S Kern; Edward Feener; Lloyd P Aiello; Jennifer K Sun; George Liang King

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6427.

ARVO Annual Meeting Abstract July 2019

Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema

Nivetha Murugesan; Allen C Clermont; Stephen J Pethen; Lily Li; Edward J Duckworth; Sally L Hampton; Edward Feener

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2596.

ARVO Annual Meeting Abstract July 2019

Complement C3 mediates vascular endothelial growth factor (VEGF) induced retinal edema but not visual dysfunction in mice.

Allen C Clermont; Alex Feener; Nivetha Murugesan; Lloyd P Aiello; Edward Feener

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2791.

ARVO Annual Meeting Abstract July 2018

Vascular endothelial growth factor (VEGF) mediates electroretinogram (ERG) dysfunction in mice through plasma kallikrein and nitric oxide

Allen C Clermont; Fabricio Simao; Nivetha Murugesan; Paul Huang; Lloyd P Aiello; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3463.

ARVO Annual Meeting Abstract July 2018

A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema

Nivetha Murugesan; Allen C Clermont; Louise J Rushbrooke; Peter A Robson; Robrecht Thoonen; Stephen J Pethen; Sally L Hampton; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3464.

ARVO Annual Meeting Abstract June 2017

Effects of Vascular endothelial growth factor (VEGF) on electroretinogram (ERG) amplitude in rats are mediated by bradykinin.

Allen C Clermont; Nivetha Murugesan; Tuna Ustunkaya; Brianna Mastromarino; Lloyd P Aiello; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5347.

Genetics June 2017

Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase

PDF

Marie H. Solheim; Allen C. Clermont; Jonathon N. Winnay; Erlend Hallstensen; Anders Molven; Pål R. Njølstad; Eyvind Rødahl; C. Ronald Kahn
TAGS: 1-phosphatidylinositol 3-kinase, congenital abnormality, eye, iris, mice, mutation, short syndrome, immune reconstitution inflammatory syndrome, intraocular pressure
Invest. Ophthalmol. Vis. Sci.. 2017; 58(7):3100-3106. https://doi.org/10.1167/iovs.16-21347

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Title: Complement component 3 (C3) is increased in vitreous in diabetic macular edema and is required for bradykinin (BK)-induced retinal edema.

Nivetha Murugesan; Allen C Clermont; Takeshi Kita; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Increased FXII activity in vitreous of patients with Diabetic Macular Edema (DME) and in animal models of VEGF- and bradykinin-induced retinal edema

Tuna Ustunkaya; Nivetha Murugesan; Allen C Clermont; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4183.

ARVO Annual Meeting Abstract September 2016

Vascular endothelial growth factor (VEGF) and bradykinin induce increased electroretinogram amplitude and decreased visual acuity.

Allen C Clermont; Nivetha Murugesan; Cheng-mao Lin; Sarah R Sheskey; David A Antonetti; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

Retina May 2016

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor–Induced Retinal Dysfunction and Thickening

PDF

Allen Clermont; Nivetha Murugesan; Qunfang Zhou; Takeshi Kita; Peter A. Robson; Louise J. Rushbrooke; D. Michael Evans; Lloyd Paul Aiello; Edward P. Feener
TAGS: edema, plasma kallikrein, vascular endothelial growth factor a, mice, retina
Invest. Ophthalmol. Vis. Sci.. 2016; 57(6):2390-2399. https://doi.org/10.1167/iovs.15-18272

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2015

Vascular endothelial growth factor (VEGF)- and the kallikrein kinin system (KKS)- induced neuronal dysfunction in a rodent model of retinal edema.

Allen C Clermont; Nivetha Murugesan; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5487.

ARVO Annual Meeting Abstract June 2015

Proteomic characterization of retinal edema in rats

Nivetha Murugesan; Allen C Clermont; LeiLei Sun; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4693.

ARVO Annual Meeting Abstract April 2014

Role of Akt in VEGF-, bradykinin-, and diabetes-induced retinal dysfunction and edema

Ward Fickweiler; Allen C Clermont; Nivetha Murugesan; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2256.

ARVO Annual Meeting Abstract April 2014

Plasma kallikrein (PKal) deficiency ameliorates the effects of vascular endothelial growth factor (VEGF) on retinal hyperpermeability and edema.

Allen C Clermont; Qunfang Zhou; Nivetha Murugesan; Ward Fickweiler; Edward P Feener

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):594.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Factor XIIa inhibition protects against VEGF-induced neuroretinal dysfunction in mice

Factor XII contributes to VEGF-induced retinal edema and neuroretinal responses in mice

Vascular Density of Deep, Intermediate and Superficial Vascular Plexuses Are Differentially Affected by Diabetic Retinopathy Severity

Vascular endothelial growth factor (VEGF) induces retinal edema and neuroretinal dysfunction in diabetic rats.

Novel oral plasma kallikrein inhibitor KV998076 is protective against intravitreal VEGF and TNFα induced retinal edema and neuroretinal dysfunction

Identification of Photoreceptor Protein, Retinol Binding Protein 3 (RBP3), as a Protective Factor for Diabetic Retinopathy

Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema

Complement C3 mediates vascular endothelial growth factor (VEGF) induced retinal edema but not visual dysfunction in mice.

Vascular endothelial growth factor (VEGF) mediates electroretinogram (ERG) dysfunction in mice through plasma kallikrein and nitric oxide

A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema

Effects of Vascular endothelial growth factor (VEGF) on electroretinogram (ERG) amplitude in rats are mediated by bradykinin.

Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase

Title: Complement component 3 (C3) is increased in vitreous in diabetic macular edema and is required for bradykinin (BK)-induced retinal edema.

Increased FXII activity in vitreous of patients with Diabetic Macular Edema (DME) and in animal models of VEGF- and bradykinin-induced retinal edema

Vascular endothelial growth factor (VEGF) and bradykinin induce increased electroretinogram amplitude and decreased visual acuity.

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor–Induced Retinal Dysfunction and Thickening

Vascular endothelial growth factor (VEGF)- and the kallikrein kinin system (KKS)- induced neuronal dysfunction in a rodent model of retinal edema.

Proteomic characterization of retinal edema in rats

Role of Akt in VEGF-, bradykinin-, and diabetes-induced retinal dysfunction and edema

Plasma kallikrein (PKal) deficiency ameliorates the effects of vascular endothelial growth factor (VEGF) on retinal hyperpermeability and edema.

To View More...

You must be signed into an individual account to use this feature.